Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

NCT07058779 | Recruiting Phase 1

• 1 other identifier: SSS55-101
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.

Conditions

Safety Issues

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of a single intravenous infusion of SSS55 injection in healthy adult subjects in China

  Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  22days

Secondary Outcomes (3)

• To evaluate the pharmacokinetic (PK) characteristics of SSS55 injection after a single intravenous infusion in healthy adult subjects in China

  22days

• To evaluate the pharmacodynamic characteristics of SSS55 injection after a single intravenous infusion in healthy adult subjects in China

  22 days

• To evaluate the ADA of SSS55 injection after a single intravenous infusion in healthy adult subjects in China

  22days

Study Arms (4)

Low-dose group

EXPERIMENTAL

dose1

Drug: SSS55

middle-dose group

EXPERIMENTAL

dose 2

Drug: SSS55

high-dose group

EXPERIMENTAL

dose 3

Drug: SSS55

Higher-dose group

EXPERIMENTAL

dose 4

Drug: SSS55

Interventions

SSS55 DRUG

SSS55 is an injection targeting complement C3b

Also known as: SSS55 injection

Higher-dose group; Low-dose group; high-dose group; middle-dose group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects aged 18 to 45 years old (including the boundary value), regardless of gender;
• The subjects voluntarily participated in the clinical trial and signed the informed consent form;
• Men with a weight of ≥50 kg, women with a weight of ≥45 kg, and those with a body mass index (BMI) ranging from 19 to 28 kg/m2 (including the critical value);
• Those who underwent vital sign assessment, physical examination, blood routine, urine routine, blood biochemistry, coagulation function, pregnancy examination (for women of childbearing age), 12-lead ECG, chest X-ray/lung CT during screening, and the results showed no abnormalities or the abnormalities had no clinical significance;
• Be willing to receive the MV-ACYW meningococcal vaccine and pneumococcal vaccine 14 days or more before randomization.

You may not qualify if:

• \) Those with a clear history of drug or food allergies, or a known history of hypersensitivity reactions that are clinically significant to the research intervention measures or related compounds or commonly used antibacterial agents;
• \) Those with a history of any serious clinical diseases in the past or present, including but not limited to those in the digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, immune system, neuropsychiatric system, hematological system, etc. (except those deemed eligible for enrollment by the researcher);
• \) First-degree relatives with a known history of meningococcal infection or a history of meningococcal infection;
• \) Those with contraindications to meningococcal vaccination (with a history of epilepsy or other brain diseases, etc.);
• \) There was or suspected active viral, bacterial, fungal or parasitic infection within 14 days prior to screening, including herpes, shingles or cold sores;
• \) A history of recurrent infections of unknown cause; Or systemic antibiotics (intravenous antibiotics, oral antibiotics, etc., excluding topical application antibiotics) have been used within 90 days before administration;
• \) There is a history of Gilbert syndrome or the researcher assesses that it meets the diagnostic criteria for the disease;
• \) Received treatment with blood products within 6 months prior to administration;
• \) Those who have undergone major surgical operations within 4 weeks prior to administration or have not fully recovered from any previous invasive procedures;
• \) Suffering from syphilis (Treponema pallidum antibody positive) or AIDS (HIV antibody positive), or active hepatitis C (hepatitis C virus antibody positive), or active hepatitis B (hepatitis B surface antigen positive);
• \) A history of malignant tumors in the past or present;
• \) Any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or health supplements have been used within 2 weeks before administration (if determined by the investigator, the time interval from the start of administration of the drug in this trial \> Five half-lives, and the corresponding subjects can also be enrolled.

Sponsors & Collaborators

• Shenyang Sunshine Pharmaceutical Co., LTD.: lead

Study Sites (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Central Study Contacts

Ding Chief Pharmacist, Doctor of Medicine

CONTACT

86-13761642319; shiyiphase1@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 26, 2025
• First Posted: July 10, 2025
• Study Start: August 4, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: March 2, 2026

Record last verified: 2026-02

Locations

CN (1)